Abstract
Objective
Acarbose is a glucosidase inhibitor that slows carbohydrate digestion. It could thus be effective to promote remission of dumping syndrome (DS). Previous studies associating acarbose and late dumping, although not early dumping, have been reported. Herein, we aimed to evaluate the role of acarbose in dumping syndrome prevention and treatment and in resistive exercises resistance in bariatric subjects.
Methods
Bariatric patients with DS and complete adherence to diet plan and resistive exercises were included (n=25). Number of early and late episodes, self-referred intensity of each episode, and ability to increase intensity of resistive exercise were evaluated, on a 0–10 scale. Acarbose was administered orally (50 mg) for 6 months, 4–5 times a day before meals.
Results
Acarbose administration was associated with a decrease in the number of early (2.18–0.31) and late (2.79–0.12) episodes per week and intensity of each episode (6.10–1.65) and an increase in the ability to perform resistive exercises (3.03–7.12). Complete remission of DS was seen in 21 patients (84%), which persisted for 6 months with the use of acarbose.
Conclusion
Acarbose prevented dumping in almost all studied subjects and helped improve exercise capacity.
Introduction
Dumping syndrome (DS) is the effect of rapid gastric emptying with consequent hyperosmolar jejunal chime, inappropriate gut-hormone release, and rapid glucose absorption, and it is particularly common among post-bariatric surgery patients, as it occurs in up to 75% of patients after Roux-en-Y gastric bypass surgery.Citation1–Citation5 DS can be either early – when symptoms happen between 30 and 60 min as a result of rapid instillation of meals into the small bowel and decreased blood volume due to intraluminal fluid sequestration, and most symptoms are abdominal (bloating and abdominal pain) and systemic (palpitations, fatigue, tachycardia, lightheadedness, and syncope) – or late, which is thought to be caused by hyperinsulinemic hypoglycemia, and the most commonly observed symptoms and signs are due to neuroglycopenia and hyperadrenergic state (decreased consciousness, shakiness, and difficulty to concentrate). It is important to note that often patients may present both early and late DS at the same meal. DS reduces the quality of life as symptoms are usually severe and can limit sports capacity and everyday activities.Citation1–Citation7
Current approaches for DS treatment comprise dietary recommendationsCitation3,Citation4,Citation6 such as small and frequent meals, inclusion of fiber and protein in every meal, and ingestion of guar gum and pectin. Pharmacological options for DS are limited and mostly symptomatic, such as tincture opium for diarrhea,Citation7 meclizine, promethazine, and proton pump inhibitors.Citation3,Citation6 Octreotide has been shown to be markedly effective to improve the quality of life in DS,Citation8,Citation9 despite commercial and financial limitations and significant side effects. However, most of the potential benefits of the current approaches are observed only in late DS, but not in the early DS, nor in exercise-induced dumping, a condition described that affects some post-bariatric athletes,Citation10–Citation12 specially during intense physical activities,Citation10,Citation11 whose pathophysiology remains uncertain but may be due to exacerbation of gastrointestinal physiological adaptions to physical activity.Citation11
Indeed, there is a lack of previous papers focusing on the management of exercise-induced DS, except for expert opinion and experience and nonscientific recommendations.Citation13 A recent review on management of DS has been published and reinforces the lack of papers about correlations between physical activity and DS.Citation4
Acarbose, a glucosidase inhibitor that slows carbohydrate digestion and is primarily prescribed as an antidiabetic agent has been shown to be effective in late DS,Citation6,Citation14–Citation16 but has not been studied for early DS; rationale of protection of late dumping by acarbose is based on the fact that this drug delays glucose absorption; thus, hyperinsulinemic hypoglycemia due to excessive insulin release by incretin and by direct glucose stimulation is prevented by acarbose.Citation14,Citation16 Furthermore, acarbose has the potential benefit to prevent beta-cell hypertrophy and hyperplasia; indeed, hyperinsulinemic hypoglycemia, one of the main cornerstone aspects of DS, has a significant improvement by acarbose.Citation6,Citation17,Citation18
Other studies with acarbose in DS have not been performed, as severe side effects such as excessive flatulenceCitation14 had limited its use. Despite the benefits, acarbose has not been standardized as part of protocols to manage DS symptoms.Citation3
Despite the symptomatic limitations of acarbose, the lack of efficient options to prevent and improve DS and the strong likelihood of acarbose to improve both early and late DS encouraged us to undertake this study. Therefore, we aimed to evaluate the role of acarbose in prevention and treatment of DS and in resistive exercises resistance in bariatric subjects.
Methods
Selection of subjects
Patients who previously underwent Roux-en-Y gastric bypass surgery, achieved body weight goal (body mass index <27 kg/m2 for men and <25 kg/m2 for women), had a confirmed diagnosis of DS and were refractory to diet recommendations were initially selected. Inclusion criteria were the complete adherence to an isocaloric (calculated by indirect calorimetry) and high protein (1.5–1.8 g/kg/day) diet plan, proposed resistive exercises (frequency, intensity, and exercise prescription varied among individuals), and age between 18 and 80 years. Patients who lacked regular follow-up were excluded.
Intervention
Fifty milligrams of acarbose was orally administered 4–5 times a day before meals for 6 months. For those patients who presented with severe flatulence, 120 mg simethicone (b.i.d.) was additionally prescribed. The dose of 50 mg before meals has been extensively studied and standardized,Citation14–Citation16 whereas the addition of simethicone was thought to attenuate the most important adverse effects of acarbose use (abdominal cramps, bloating, and flatulence).
Evaluated aspects
Multiple patterns of DS were evaluated: 1) number of early (0–45 min) DS episodes per week and 2) number of late (45–240 min) DS episodes a week. The DS severity evaluation methods were 1) self-referred intensity of each episode: rated from 1 (almost asymptomatic) to 10 (loss of conscious), 2) Sigstad’s scoring system to evaluate diagnosis and intensity of DS (shock +5; fainting, syncope, or unconsciousness +4; desire to lie down +4; dyspnea +3; weakness +3; sleepiness, apathy +3; palpitations +3; restlessness +2; dizziness +2; headaches +1; warm, clammy skin, or pallor +1; nausea +1; abdominal fullness +1; borborygmus +1; eructation −1; vomiting −4), and 3) ability to perform resistive exercises: rated from 0 (any effort induces DS symptoms) to 10 (no symptoms, even in intensive weight lifting). Subjects were prospectively instructed to evaluate and write down the frequency and severity of DS episodes and to bring the results at each visit, which happened every 2 weeks for 6 months. We proposed that those patients who presented a significant improvement of DS symptoms could continue the therapy after the end of the study. In each visit, subjects were actively queried about missing doses and irregular use.
Ethical approval
The proposed study protocol did not provide new or experimental therapies, but analyzed standardized modalities, and therefore approval from an ethics committee was not required. The exemption was issued by the national review board and ethics committee system (Sistema CEP-CONEP – Plataforma Brasil), which has formally authorized the intervention without submission to an ethics committee, but required that we provide subjects written informed consent to participate in the study, and containing all the benefits and possible harmful effects of the use of acarbose. We confirm that every patient was fully aware of the purpose of the study and signed informed consent to participate, prior to beginning the use of acarbose. The principles outlined in the Declaration of Helsinki were followed.
Results
A total of 25 subjects (13 men and 12 women; mean age, 37.2 years) were regularly followed up. None of the patients withdrew or missed doses. Among these, 7 presented with severe flatulence and one patient showed persistent flatulence despite simethicone prescription. None of the subjects stopped acarbose use owing to side effects. Significant improvements were seen in all analyzed parameters: 1) mean number of early DS episodes per week (2.18–0.31; 85.8% reduction; p<0.001), 2) mean number of late DS episodes per week (2.79–0.12; 95.7% reduction; p<0.001), 3) self-referred intensity of each episode (6.1–1.65; 73.0% reduction; p<0.001), 4) Sigstad’s score (2.36–0.32; 86.4% reduction; p<0.001), and 5) ability to perform resistive exercises (3.03–7.12; 135.0% improvement; p<0.001). These results are summarized in . Improvements were observed from the beginning of the use of acarbose and persisted throughout the 6 months of therapy.
Table 1 Summary of the results
Complete remission of DS (except during exercises) was observed in 21 patients (84% of analyzed subjects), which persisted throughout the 6 months of acarbose use in all 21 subjects.
Discussion
Bariatric surgery reduces metabolic, cardiovascular, and neoplastic risks, overall mortality, and substantially improves the quality of life. However, DS has limited the everyday activities of several post-bariatric surgery patients and impaired expected improvement in various aspects of quality of living.Citation1,Citation2 Little effort has gone into finding effective options to decrease severity and frequency of DS events; moreover, the frequency of severe DS and number of DS-related deaths are likely under reported. Acarbose has been shown to be an inexpensive option that substantially improves overall quality of life of post-bariatric subjects affected by DS, particularly the late dumping.Citation14–Citation16
Although early DS is not related to hypoglycemia, the complete understanding of its pathophysiology is still lacking and is assumed to be due to a contraction of the plasma volume as a result of the fluid shifts into the gastrointestinal tract,Citation19 which does not fully justify the signs and symptoms observed in early dumping. Possibly, the delay of autonomic and incretin hormones stimulations (once incretins also induce sympathetic and autonomic effects) may at least partly explain the improvement observed in early DS; in fact, increased release of multiple gastrointestinal hormones, including vasoactive agents, incretins, and glucose modulators, in early DS has been described.Citation4,Citation20–Citation22
To the best of our knowledge, the novelties of this study are that it has been the first to show 1) the important improvement of early DS and complete remission of DS in most patients (84.0%) who were treated with acarbose and 2) the improvement of exercise capacity among DS subjects who triggered or worsened DS symptoms during physical exertion. Subjective patient testimonies express relevant change in everyday life and the desire to maintain long-term therapy.
Regular intake was observed in all included subjects, probably due to the benefits provided by this drug. Likewise, all patients maintained the use of acarbose after the end of the study, once the improvement observed was significant that it would be an ethical issue to interrupt the proposed therapy. Therefore, we were not able to predict the effects of acarbose discontinuation, although some improvement could be potentially observed after acarbose discontinuation, given the fact that hyperfunction and hypertrophy of the beta-cells, related to rapid glucose absorption in bariatric subjects, are blunted by this drug.
A limitation of the study is that we did not include a control group to study the possible placebo effect of acarbose, although it is unlikely that the observed improvements are due to placebo effect.
Conclusion
Acarbose induced complete remission of DS in most subjects and substantially decreased the frequency and intensity of both early and late DS events. Further prospective randomized placebo-controlled double-blind clinical trials with monitoring of vital signs and glucose should be performed in order to confirm our findings. Until then, acarbose may be treated as an option for refractory DS subjects.
Acknowledgments
We acknowledge the support of the Corpometria Institute staff team, who helped to manage all the subjects who were included in this study.
Disclosure
The authors report no conflicts of interest in this work.
References
- Ukjela A Dumping syndrome: pathophysiology and treatment Nutri Clin Pract 2005 20 5 517 525
- Abell TL Minocha A Gastrointestinal complications of bariatric surgery: diagnosis and therapy Am J Med Sci 2006 331 4 214 218 16617237
- Tack J Arts J Caenepeel P De Wulf D Bisschops R Pathophysiology, diagnosis and management of postoperative dumping syndrome Nat Rev Gastroenterol Hepatol 2009 6 10 583 590 19724252
- Van Beek AP Emous M Laville M Tack J Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management Obes Rev Epub 2016 10 17
- Lass A Life after bariatric surgery Adv Nurse Pract 2008 16 6 47 48 50 51
- Berg P McCallum R Dumping syndrome: a review of the current concepts of pathophysiology, diagnosis, and treatment Dig Dis Sci 2016 61 1 11 18 26396002
- Parrish CR The clinician’s guide to short bowel syndrome Pract Gastroenterol 2005 29 9 67
- Didden P Penning C Masclee AAM Octreotide therapy in dumping syndrome: analysis of long-term results Aliment Pharmacol Ther 2006 24 9 1367 1375 17059518
- Li-Ling J Irving M Therapeutic value of octreotide for patients with severe dumping syndrome – a review of randomised controlled trials Postgrad Med J 2001 77 909 441 442 11423592
- Oliveira EP Burini RC Food-dependent, exercise-induced gastrointestinal distress J Int Soc Sports Nut 2011 8 12
- Livhits M Mercado C Yermilov I Exercise following bariatric surgery: systematic review Obes Surg 2010 20 5 657 665 20180039
- Welch G Wesolowski C Piepul B Kuhn J Romanelli J Garb J Physical activity predicts weight loss following gastric bypass surgery: findings from a support group survey Obes Surg 2008 18 5 517 524 18365295
- Women Fitness Magazine 2016 Feb print edition. Available from: http://www.womenfitness.net/dumping_syndrome.htm https://sites.google.com/a/brnamj1.com/health/health-a-z/d/symptoms-causes-risk-factors-complications-preparing-for-your-appointment-tests-and-diagnosis-treatments-and-drugs-lifestyle-and-home-remedies-coping-and-support-prevention-12 Accessed October 29, 2016
- De Cunto A Barbi E Minen F Ventura A Safety and efficacy of high-dose acarbose treatment for dumping syndrome J Pediatr Gastroenterol Nutr 2011 53 1 113 114 21694549
- Hasegawa T Yoneda M Nakamura K Long-term effect of alpha-glycosidade inhibitor on late dumping syndrome J Gastroenterol Hepatol 1998 13 12 1201 1206 9918426
- Wang C Pang S Jiang Q Duan G Sun Y Li M Treatment with acarbose in severe hypoglycaemia due to late dumping syndrome West Indian Med J 2013 62 9 861 863 25117397
- Ceppa EP Ceppa DP Omotosho PA Dickerson JA2nd Park CW Portenier DD Algorithm to diagnose etiology of hypoglycemia after Roux-en-Y gastric bypass for morbid obesity: case series and review of the literature Surg Obes Relat Dis 2012 8 5 641 647 21982939
- Mala T Postprandial hyperinsulinemic hypoglycemia after gastric bypass surgical treatment Surg Obes Relat Dis 2014 10 6 1220 1225 25002326
- Elrazek AE Elbanna AE Bilasy SE Medical management of patients after bariatric surgery: principles and guidelines World J Gastrointest 2014 6 11 220 228
- Tack J Gastric motor disorders Best Pract Res Clin Gastroenterol 2007 21 4 633 644 17643905
- Mayer EA Thompson JB Jehn D Reedy T Elashoff J Meyer JH Gastric emptying and sieving of solid food and pancreatic and biliary secretion after solid meals in patients with truncal vagotomy and antrectomy Gastroenterology 1982 83 1 Pt 2 184 192 6919504
- Lawaetz O Blackburn AM Bloom SR Aritas Y Ralphs DN Gut hormone profile and gastric emptying in the dumping syndrome. A hypothesis concerning the pathogenesis Scand J Gastroenterol 1983 18 1 73 80 6372067